Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

NCT04247542 - Ibezapolstat vs Vancomycin & Clostridioides difficile infection (CDI) (initial)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Clostridioides difficile infection (CDI) is a common health-care-associated and community-acquired disease with few antibiotic treatment options (1)

NCT04247542 - Ibezapolstat vs Vancomycin & Clostridioides difficile infection (CDI) (initial) is a randomized clinical phase II treatment trial studying Ibezapolstat vs. Vancomycin in patients with Clostridioides difficile infection (CDI) (initial)

Initial clinical cure maintained for at least 48 h after the end of treatment (1)

Between March 12, …

Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study
Eubank et al. 2025 Lancet Microbe 6: 101126

7/1/2026